CFX™ (Cardiac Fibroblast matriX) TECHNOLOGY
CFX represents a groundbreaking therapeutic biomaterial developed using induced pluripotent stem cell technology. This innovative material has demonstrated remarkable potential in addressing cardiovascular diseases, particularly heart failure. Prevention of Heart Failure When administered locally in animal models of heart failure, CFX has shown the ability to prevent pathological changes that typically lead to heart failure following acute injuries such as myocardial infarction. Remuscularization of Scarred Myocardium
In cases of chronic heart failure, CFX, when used in combination with therapeutic stem cells, has demonstrated the capacity to remuscularize scarred heart tissue, effectively restoring heart function. While CFX presents various commercial opportunities, the primary focus is on providing a highly effective and safe product to regenerative medicine companies, both early and late-stage, who share the goal of developing and marketing therapeutic solutions to address the cardiovascular disease epidemic.
The CFX technology is exclusively licensed by Cellular Logistics and is protected by issued patents and pending patent applications in the United States and in foreign jurisdictions. This robust intellectual property portfolio underscores the innovative nature of CFX and its potential to revolutionize cardiovascular disease treatment.
CFX™ Format and Delivery Flexibility
CFX™ Advantages
Immune Privilege and Versatility - CFX is a cell-free product that exhibits immune privilege, allowing for administration to any recipient without the need for immunosuppressive medications. This unique property enables broad clinical application across diverse patient populations.
Immunomodulatory Effects - CFX modulates macrophages, key immune cells involved in the healing process. By promoting the expression of healing properties in macrophages, CFX facilitates a more favorable wound-healing environment.
Tailored Formulations – CFX product formulations have been carefully designed to optimize clinical applications while considering practical, patient-centered aspects of therapeutic delivery. This approach ensures that CFX can be effectively utilized in various medical scenarios.
Versatile Delivery Options – CFX is available in two primary forms:
Injectable particulate:
- Particle sizes can be easily tuned based on specific clinical needs
- Compatible with 25G and 27G needles, including long, steerable, needle-tipped catheters
- Can be injected alone or in combination with stem cells
- Enhances stem cell retention by preventing rapid egress through vasculature and lymphatics in the beating heart
Thin, pliable patch:
- Slightly larger than a contact lens
- Easily handled by surgeons during application on the heart surface
- Does not require sutures or glue for application
Cell Binding Properties - CFX effectively binds to various cell types, including stem cells. This binding capability improves the retention of injected stem cells, particularly in dynamic environments like the beating heart.
Manufacturing and Stability - CFX offers several advantages from a production and storage perspective such as well-defined constituent proteins, highly reproducible and scalable production methods, shelf-stable at room temperature, ready for transition to cGMP manufacturing facilities. These characteristics ensure consistent product quality and facilitate widespread clinical use.